Sumitomo Dainippon Pharma Co., Ltd. announced that at its meeting held on February 24, 2017, the board of directors decided to change the following representative directors and executive officers. With effect from April 1, 2017, the retirement of one of the current representative directors, Hiroshi Noguchi, from executive officer and representative director, a new representative director will be appointed. Hiroshi Nomura appointed as the representative director, executive vice president from member, board of directors, executive vice president of the company. Hiroshi Noguchi appointed as member, board of directors from representative director, senior executive vice president of the company. New executive officers with affect from April 1, 2017: Mitsuyuki Taniguchi (currently deputy executive director, sales & marketing division); Atsuko Higuchi (currently senior communication officer); and Shigeyuki Nishinaka (currently senior director, global business development). Retiring executive officers with effect from March 31, 2017: Hiroshi Noguchi (currently representative director, senior executive vice President); Masaru Ishidahara (currently member, board of directors, senior executive officer) and Yoshinori Oh-e (currently senior executive officer).
Sumitomo Pharma Co., Ltd. (formerly Sumitomo Dainippon Pharma Co., Ltd.) specializes in development, manufacturing and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- pharmaceuticals (92.9%): for cardiovascular, gastrointestinal and infectious diseases, central nervous systems disorders and allergies treatment;
- other (7.1%): veterinary drugs, food additives, industrial chemical products, etc.
Net sales are distributed geographically as follows: Japan (39.8%), the United States (50.4%), North America (0.9%) and other (8.9%).